Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis (Nasdaq: ZNTL) announced an inducement equity grant on May 1, 2026. The Compensation Committee awarded non-qualified stock options for 26,000 shares to one newly hired employee under the 2022 Inducement Plan, with an exercise price of $4.09 per share.
The options carry a 10-year term and vest over four years: 25% at the first anniversary and the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Zentalis (Nasdaq: ZNTL) announced that an abstract reporting results from Part 1 of the Phase 1b MUIR trial of azenosertib plus paclitaxel in platinum-resistant ovarian cancer (PROC) was accepted for presentation at the ASCO 2026 Annual Meeting on June 1, 2026.
The poster (Abstract 5529, Poster Board 195) will be presented during the Gynecologic Cancer poster session from 9:00–12:00 CDT and highlights combinability and activity of the regimen in an all-comer setting.
Zentalis (Nasdaq: ZNTL) will present preclinical and real-world data at AACR 2026 on azenosertib, a WEE1 inhibitor. Preclinical TNBC models showed antitumor activity (42–99% TGI) and 7/8 complete responses in an ADC-resistant PDX with azenosertib+enfortumab vedotin. Real-world ovarian cancer data show Cyclin E1-positive patients have shorter time to next treatment (13.2/14.9 vs 19.5 months; p=0.002).
The posters detail combination strategies in TNBC and unmet need in Cyclin E1-positive ovarian cancer relevant to ongoing DENALI and ASPENOVA programs.
Zentalis (Nasdaq: ZNTL) selected 400mg QD 5:2 azenosertib monotherapy as the pivotal dose for Cyclin E1-positive platinum-resistant ovarian cancer based on a prespecified DENALI Part 2a interim analysis.
The company reported a clearly differentiated response rate at 400mg versus 300mg with comparable safety, no treatment-related deaths, plans to include Part 2a data in the full Part 2 dataset, will initiate Part 2c enrollment in Q2 2026, and expects a DENALI Part 2 topline readout by year-end 2026.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on April 1, 2026 that its Compensation Committee granted non-qualified stock options for an aggregate of 36,000 shares to two newly hired employees under the 2022 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4).
The options carry a $2.57 exercise price (closing price on the grant date), a 10-year term, and four-year vesting (25% after one year, remainder monthly over three years), subject to continued service.
Zentalis (Nasdaq: ZNTL) reported full-year 2025 results and clinical progress on azonosertib, a WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. Cash, cash equivalents and marketable securities totaled $245.9 million as of December 31, 2025, with runway projected into late 2027.
Key 2026 milestones include DENALI Part 2a dose confirmation in 1H 2026, DENALI Part 2 topline readout by year-end 2026, and initiation of Phase 3 ASPENOVA in 1H 2026; MUIR Part 2 combination study is ongoing.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) will present two scientific posters at the AACR Annual Meeting in San Diego, April 17-22, 2026. One poster reports preclinical data on azenosertib combination strategies for Triple-Negative Breast Cancer; the other reports real-world Cyclin E1 biomarker findings in ovarian cancer.
Poster details include presentation dates, times, abstract numbers, and presenters; posters will be posted on the company Supporting Publications page when presented.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced management participation in three investor conferences in late February and March 2026. The schedule includes virtual and in-person fireside discussions at Oppenheimer (Feb 25), TD Cowen (Mar 3) and Leerink Partners (Mar 9).
According to the company, live webcasts and archived recordings will be available for at least 30 days under the Investors & Media "Events & Presentations" tab.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11, 2026 at 3:30 p.m. ET in New York. A live webcast and archived recording will be available under the company's Investors & Media "Events & Presentations" tab for at least 30 days.
Zentalis (Nasdaq: ZNTL) provided a corporate update on January 6, 2026 outlining 2026 milestones for azenosertib, its investigational WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Key points: DENALI Part 2a enrollment completed with dose confirmation expected in 1H 2026, DENALI Part 2 topline readout expected by year-end 2026 (could support accelerated approval, subject to FDA feedback), and initiation of the randomized Phase 3 ASPENOVA trial planned in 1H 2026. The company reported $280.7M cash and equivalents as of Sept 30, 2025, providing an estimated runway into late 2027.